Abstracts Archive - Page 401 of 2607 - ACR Meeting Abstracts

Abstract Number: 1364 • ACR Convergence 2023
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴, Rebecca Jacobson¹ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…
Abstract Number: 1190 • ACR Convergence 2023
Worsening of Pain as Perceived by Patients Is Not Reflected by an Annual Standardized Questionnaire
Coen van der Meulen¹, Lotte van de Stadt², Frits Rosendaal¹ and Margreet Kloppenburg¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Reade, Amsterdam, Netherlands
Background/Purpose: The course of pain in hand osteoarthritis (OA) is often investigated with repeated validated pain questionnaires. However, it is unknown whether these questionnaires reliably…
Abstract Number: 1334 • ACR Convergence 2023
Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses
Marina Birck¹, Luck Lukusa², Michal Abrahamowicz³, Gilles Boire⁴, Denis Choquette⁵, Walter P. Maksymowych⁶ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²RI-MUHC, Montreal, QC, Canada, ³McGill University, Verdun, QC, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…
Abstract Number: 1382 • ACR Convergence 2023
Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome
Qinghong Liu¹ and Jing He², ¹Peking University People's Hospital, Beijing, China, ²Peking University People’s Hospital, Beijing, China
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by systemic involvement and lacks effective treatment options. The Janus kinase (JAK) pathway plays a…
Abstract Number: 1386 • ACR Convergence 2023
Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
Huseyin Berk Degirmenci¹, Christine E. Peloquin², Sara Lodi², Pedro Machado³, S. Reza Jafarzadeh⁴, Tuhina Neogi⁵, Lianne Gensler⁶, Maureen Dubreuil⁷ and Jean Liew², ¹St. Elizabeth's Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁷Department of Rheumatology, Boston University School of Medicine, Milton, MA
Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…
Abstract Number: 1385 • ACR Convergence 2023
Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers
Joerg Ermann¹, Stephanie Sinnappan² and Alexandra Forte³, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: Several sets of treatment recommendations for axial spondyloarthritis and ankylosing spondylitis (axSpA/AS) have been published. Clinical practice guidelines are not followed consistently by health…
Abstract Number: 1381 • ACR Convergence 2023
Fatigue and Associated Factors in Patients with Primary Sjogren’s Syndrome Compared to Secondary Sjogren’s Syndrome
Hyeji Jeon, Hyun-Sook Kim and Kyung-Ann Lee, Soonchunhyang University Seoul Hospital, Seoul, South Korea
Background/Purpose: Fatigue is one of the dominant symptoms of patients with Primary Sjogren's syndrome (pSS). However, whether fatigue is specific to pSS compared to secondary…
Abstract Number: 1375 • ACR Convergence 2023
The Relative Burden of Fatigue Is Associated with High TSH/fT4 Ratio in Korean Patients with Primary Sjogren’s Syndrome
Jee-in Lee¹, Se Rim Choi², You-Jung Ha², Eun Ha Kang³, Keun-Suh Kim⁴, Joon Young Hyon⁵ and Yun Jong Lee⁶, ¹Seoul National University of Bundang Hospital, Seongnam, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnamsi, South Korea, ³Seoul National University Bundang Hospital, Seongnam, South Korea, ⁴Department of Periodontology, Section of Dentistry, Seoul National University Bundang Hospital, Seongnamsi, South Korea, ⁵Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnamsi, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea
Background/Purpose: To investigate the prevalence of anti-thyroid autoantibodies, abnormal thyroid function, and their clinical impacts in Korean patients with primary Sjögren's syndrome (pSS). Methods: One…
Abstract Number: 1368 • ACR Convergence 2023
Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Benjamin A Fisher¹, Linda Stone², Jessica Marvel³, Pushpendra Goswami⁴, Monia Steenackers⁴, Gayle Kenney⁴, Chiara Perella⁵, Wolfgang Hueber⁴, Chloe Howse⁶, Elizabeth Gargon⁶, Aishwarya Chohan⁶, Megan Mayhew⁶ and Nicola Williamson⁶, ¹University of Birmingham, Birmingham, United Kingdom, ²The British Sjogren’s Syndrome Association, Birmingham, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Riehen, Switzerland, ⁶Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom
Background/Purpose: Sjögren's is a heterogenous chronic auto-immune disease, characterized by excessive dryness of the eyes and mouth, as well as systemic complications which can significantly…
Abstract Number: 1298 • ACR Convergence 2023
Risk Factors Associated with Venous Thromboembolism in Rheumatoid Arthritis in Clinical Practice
Fiona Oudart¹, Marion THOMAS², Alice Combier³, Anna Molto², Yannick ALLANORE⁴ and Jérôme Avouac⁵, ¹Université Paris Cité, Paris, France, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³APHP / Cochin Hospital, Paris, France, ⁴Université Paris Cité, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Increased risk of venous thromboembolism (VTE) has been reported in rheumatoid arthritis (RA) compared to the general population. However, factors associated with the risk…
Abstract Number: 1200 • ACR Convergence 2023
Self-Reported Effectiveness of Cannabis for Arthritis-Related Pain
Kristin Wipfler¹, Joanna Zeiger² and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Pain management remains a significant challenge for individuals with rheumatic diseases (RDs), often causing patients to seek complementary or alternative treatments to traditional medications.…
Abstract Number: 1389 • ACR Convergence 2023
Low Spinal Radiographic Progression After a Mean of 15 Years of Follow-up in a Cohort of Patients with Axial Spondyloarthritis
raquel granados¹, Santiago Dans-Caballero¹, Lourdes Ladehesa Pineda², María Ángeles Puche Larrubia³, Desiree Ruiz Vilchez⁴, Maria del Carmen Abalos-Aguilera⁴, Alejandro Escudero-Contreras⁵, Eduardo Collantes Estévez⁶ and Clementina López Medina⁷, ¹Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain, ²Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ³Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁵Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, ⁶Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ⁷Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by progressive structural damage on the sacroiliac joints and/or the spine. Conventional radiology allows to assess radiology through available…
Abstract Number: 1388 • ACR Convergence 2023
Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI
Ummugulsum Gazel¹, Kristen Noges², Burak Ayan², Gizem Ayan³, Olivier Brown¹, Andra Smith¹ and sibel aydin⁴, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Hacettepe University Faculty of Medicine Division of Rheumatology, Ankara, Turkey, ⁴University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Approximately 50% of PsA patients have persistent pain despite a well‐controlled inflammatory state, which has been attributed to non‐nociceptive pain and central sensitization. Enthesitis…
Abstract Number: 1390 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients suffering from ankylosing spondylitis (AS) in randomized clinical trials [1]. There is only limited…
Abstract Number: 1393 • ACR Convergence 2023
Fully Automated Detection of Active Sacroiliitis in Patients with Axial Spondyloarthritis: A Machine Learning-Based Analysis Magnetic Resonance Image
Go-Eun Lee¹, Sang-Il Choi¹, Jungchan Cho², Seon Ho Kim³, Geun Young Lee⁴ and Sang Tae Choi⁵, ¹Department of Computer Engineering, Dankook University, Seongnam, South Korea, ²School of Computing, Gachon University, Seongnam, South Korea, ³Integrated Media Systems Center, Viterbi School of Engineering, University of Southern California, Los Angeles, CA, ⁴Department of Radiology, Chung-Ang University College of Medicine, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea
Background/Purpose: Magnetic Resonance Imaging (MRI) is a crucial modality for early diagnosis of active inflammation in the sacroiliac joint in patients with axial spondyloarthritis (axSpA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].